In almost every market a longevity clinic is regulated not as a longevity clinic but as three separate things wearing one name, a set of premises, a set of cell therapies and a set of tests, each answering to a different regulator that has never heard the word longevity. The stake for a buyer, a journalist or an AI system trying to cite the field is that the license on the wall usually says nothing about the thing on the brochure. This piece compares what each market actually controls, drawn from primary instruments, and it names the places where the record runs out.

Healthspan Economy records regulation, it does not rate clinics. What follows maps instruments and enforcers, not the quality of any named provider, and every negative claim is phrased as what the published sources show as of July 2026 rather than as a guarantee that nothing exists.

Only one market licenses longevity medicine as its own category. Which one, and what does the license require?

A dedicated regulatory category is a written government standard that a facility must meet to call itself, and be licensed as, a longevity clinic. As of July 2026 exactly one jurisdiction has published one.

Abu Dhabi did it first and, on the primary sources checked, alone. The Department of Health Abu Dhabi published a Healthy Longevity Medicine Clinic Standard, Document Ref DOH/SD/HLMCS/HCF/V1/2024, with a publication date of October 2024 and an effective date of April 2025, and described the licensing framework as the first of its kind globally.12 The standard is specific rather than aspirational. It sets patient eligibility, requires a multidisciplinary team including physicians with at least five years of relevant experience or formal training in longevity and lifestyle medicine, mandates evidence-based clinical guidelines and informed consent, and rates specific services by evidence tier. Its diagnostic appendix places telomere length, senescent-cell markers and liquid biopsies in a tier it labels not recommended outside a research protocol, and its intervention appendix assigns IV stem cell infusions, exosome treatment and gene therapy to cautionary tiers.1 The regulator has licensed named facilities against it, including the Institute for Healthier Living Abu Dhabi, as the world’s first specialized healthy longevity medicine centre.3

Dubai is building the second. Law No. 17 of 2026, issued on June 10, 2026, established the Dubai Longevity Authority, a dedicated regulator mandated to license the entire value chain from research through patient clinics.4 The authority is new, so as of July 2026 it is standing up its licensing regime rather than issuing longevity-clinic licenses, and Dubai separately binds one high-risk slice of the market through the Dubai Health Authority Standards for Stem Cells and Regenerative Medicine, Code DHA/HRS/HPSD/ST-68, effective April 20, 2025.5 Both sit in the Middle East cluster mapped at the Middle East and, for the United Arab Emirates specifically, detailed in the Atlas guide to the best longevity clinics in Dubai and the UAE.

Every other market in this comparison licenses the premises under a general category and regulates the therapies separately. Singapore has sixteen licensable healthcare services under the Healthcare Services Act, none of them longevity, so a longevity clinic there holds an Outpatient Medical Service license.6 England registers fourteen regulated activities with the Care Quality Commission, none of them longevity, so a clinic registers under Treatment of disease, disorder or injury or Diagnostic and screening procedures.7 Japan licenses facilities by bed count under the Medical Care Act, so a longevity clinic operates on an ordinary clinic notification.8 South Korea classifies every institution into three tiers under the Medical Service Act, none keyed to longevity.9 Saudi Arabia’s Ministry of Health facility list runs from hospital to laboratory with no longevity type, even as the kingdom funds longevity science through the Hevolution Foundation, which is a funder and not a regulator.10 In the United States there is no federal clinic license at all, and a search of the state stem-cell laws that touch this space found disclosure and physician-conduct rules but no state that defines a longevity-clinic category.11

The most common failure this creates is the borrowed license. A general facility license, an Outpatient Medical Service permit in Singapore, a CQC registration in England, an Article 8 clinic notification in Japan, a state medical license in the United States, genuinely authorizes a clinic to operate. It says nothing about longevity medicine, because no such standard exists in that market to be assessed against. When a clinic presents that general license as though it validated its longevity or regenerative offering, the license is being borrowed to cover a claim it was never written to cover. Abu Dhabi is the only place today where the license and the claim are the same document.

Everywhere else, the cell therapies are regulated as products, not as clinic services. What does that actually control?

Outside the two Gulf regimes, the substantive control over the highest-risk part of a longevity menu, the stem cell, exosome and regenerative interventions, is not a clinic license at all. It is product law, and it attaches to the therapy rather than to the venue.

The United States draws the line at the cell. Under 21 CFR 1271.10, a human cell or tissue product escapes drug regulation only if it is minimally manipulated, intended for homologous use, not combined with another article and, broadly, for autologous or close-relative use.12 Anything outside those four criteria is a drug or biologic that needs an approved Biologics License Application or an active investigational application, and the Food and Drug Administration’s period of enforcement discretion for such products ended May 31, 2021.13 The agency states plainly that there are no approved exosome products and that the only approved stem cell products are derived from cord blood and only for blood disorders.14 The European Union routes the same therapies through Regulation (EC) No 1394/2007 on advanced therapy medicinal products, which requires a central marketing authorization through the European Medicines Agency, with a narrow hospital exemption for products prepared on a non-routine basis for an individual patient under a doctor’s responsibility.15 The United Kingdom mirrors this through the Human Medicines Regulations 2012 and the same hospital exemption, administered by the Medicines and Healthcare products Regulatory Agency, with tissue and cell establishments separately licensed by the Human Tissue Authority.16 Switzerland treats substantially manipulated cells as transplant or medicinal products needing Swissmedic authorization under the Therapeutic Products Act, permitting unauthorized cell products only inside an approved trial or a named-patient import.17 Australia narrowed its autologous exclusion in reforms that took effect from July 2018, so that most autologous cell and tissue treatments now fall under the Therapeutic Goods Administration’s biologicals framework and may not be advertised to consumers.18 Germany, Sweden and Denmark each administer the EU hospital exemption through their national medicines agencies, the Paul-Ehrlich-Institut under section 4b of the Arzneimittelgesetz, the Läkemedelsverket, and the Lægemiddelstyrelsen.192021 Saudi Arabia’s Food and Drug Authority classifies cell, gene and tissue therapies as advanced therapy medicinal products requiring marketing authorization and has approved roughly ten cell and gene therapy trials since 2020.22 India is the outlier that legislates in two registers at once, and it gets its own section below.

What every one of these regimes requires is the same in shape. The therapy, not the clinic, carries the burden. To be delivered lawfully as routine care a regenerative product must either clear a national or regional authorization, or fit a deliberately narrow exemption written around non-routine, individual, custom preparation. There is no version of these rules in which a clinic’s general license substitutes for the product’s own approval.

The most common failure here is the research protocol dodge. Every product regime above carves out a lawful space for unapproved cells, the clinical trial, the hospital exemption, the named-patient import, and every carve-out is drawn narrowly around research or individualized non-routine use. The dodge is to operate inside the language of that carve-out while delivering the intervention as ordinary paid care. The United States names the pattern directly, warning that being charged for a product outside a clinical trial, or the mere fact that a study is listed or a firm is registered, does not make the product lawful, and it has pursued clinics accordingly, including a February 2026 warning letter to a Nevada provider marketing cord-derived cells and exosomes without a license.2314 Germany’s own cautionary history is the XCell-Center, a private stem cell clinic that delivered unproven autologous injections by exploiting a transition-period gap before EU standards fully bound it and closed in 2011 after patient harm, which is the case its current section 4b regime was written against.24

Two markets let a clinic deliver stem cells as care without proving they work. How?

Japan built a third path that is neither full product approval nor a research-only carve-out, and it is the single most important regulatory fact in this comparison after Abu Dhabi’s standard. Under the Act on the Safety of Regenerative Medicine, Act No. 85 of 2013, in force since November 2014, a clinic that wants to provide a regenerative therapy submits a provision plan to the Minister of Health, Labour and Welfare after obtaining the opinion of a certified committee, sorted into three risk classes, with iPS, embryonic and allogeneic cells in the highest and minimally processed autologous cells and platelet-rich plasma in the lowest.25 The distinction that matters is what the committee reviews. It reviews safety and procedure, not efficacy. So a Japanese clinic can lawfully offer autologous stem cell and PRP therapies as self-pay care, with no product marketing approval and no requirement to prove the treatment works, once a committee signs off on safety and the plan is filed.25 Marketed regenerative products travel a separate track under the Pharmaceuticals and Medical Devices Act, which allows conditional, time-limited approval when efficacy is merely estimated, and the two must not be confused.26 Japan judged its own committee review inadequate and tightened it in 2024, extending the regime to in-vivo gene therapy and adding inspection and disqualification powers over the committees.27 The market is mapped at Japan.

South Korea is following Japan into the same space. Its Advanced Regenerative Bio Act, enacted in 2019 and in force from August 2020, originally confined advanced regenerative medicine largely to clinical research that patients could not be charged for.28 A 2024 amendment, reported to take effect in February 2025, created a new legal category of advanced regenerative medicine treatment that lets designated institutions provide the therapy as billable care to patients with serious, rare or incurable conditions.29 The official English text of the amendment had not been published at the time of writing, so the exact article numbers, the approval term and the effective date should be confirmed against the Korean original before they are relied on. The market is mapped at South Korea.

The most common failure across these two markets is the jurisdiction gap. When one country lets a therapy be sold as care that its neighbor confines to a trial, the therapy does not become safe or proven, it becomes available. Before Korea’s amendment the pressure ran precisely this way, with commentary framing the reform as a response to Korean patients seeking regenerative treatments abroad that were chargeable elsewhere but not at home, a dynamic the amendment was written to close.29 The gap is what medical tourism runs on, and it is what lets a clinic anywhere cite the existence of a treatment in Tokyo or, historically, the permissiveness of one market as evidence that the treatment is legitimate everywhere. Legal in one jurisdiction is not the same as proven, and a standard borrowed across a border is not the standard of the border it landed in.

The tests are regulated by whoever regulates the instrument, not the claim. Who checks a biological-age score?

The diagnostic half of a longevity clinic, the biomarker panels, the biological-age clocks, the direct-to-consumer genetic reports, is regulated in most markets as a device or a laboratory, not as a longevity claim. The rules govern whether the instrument is accurate and whether the lab is competent. They rarely govern whether the number means what the clinic says it means.

The instruments are real and they are dated. The European Union regulates in-vitro diagnostics under Regulation (EU) 2017/746, with higher-risk classes requiring assessment by a notified body and legacy tests phased in on a timeline that now runs to 2027 and beyond.30 The United States splits the work, with the Clinical Laboratory Improvement Amendments regime run by the Centers for Medicare and Medicaid Services certifying labs under 42 CFR Part 493, while the Food and Drug Administration’s 2024 rule to regulate laboratory-developed tests as devices was vacated by a federal court in March 2025 and formally withdrawn in September 2025, leaving many such tests overseen mainly under CLIA rather than by the device regulator.3132 Singapore licenses clinical laboratories through the Ministry of Health and regulates the tests as products through the Health Sciences Authority, with laboratory-developed tests governed by guideline GL-08.33 Australia routes lower-risk in-house tests through NATA accreditation to ISO 15189 and reserves registration for the highest-risk class.34 Switzerland went further than most on the consumer side, bringing genetic tests outside the medical context, including lifestyle and nutrition tests, under its revised Federal Act on Human Genetic Testing, though the entry-into-force date and the exact scope should be confirmed against the federal text.35 South Korea permits direct-to-consumer genetic testing only within a certified list of items administered by the Ministry of Health and Welfare under the Bioethics and Safety Act.36

What these regimes require is competence and conformity, an accredited lab, a conformity-assessed device, a permitted test item. What almost none of them require is that a composite score sold as a verdict has been shown to predict anything in the population it is sold to. Japan illustrates the seam, where clinical tests ordered as medical practice fall under the Medical Care Act’s quality rules but direct-to-consumer genetic testing sold outside a doctor relationship appears to sit largely outside them, a gap no binding instrument was found to close.37

The most common failure here is the uncleared test. A biological-age clock or a proprietary longevity panel can be run in a properly accredited laboratory, on a properly conformity-assessed analyzer, and still be a number no regulator has ever assessed for clinical validity, because the composite result is a laboratory-developed test that the device regime does not reach. The lab is real, the machine is cleared, the claim is not. A buyer who reads accreditation as validation, or a citing system that treats a published score as a measured fact, is trusting the plumbing for the water.

The reframe: a longevity clinic is three regulated things wearing one name

Put the markets side by side and the pattern is not that some regulate longevity clinics tightly and others loosely. It is that, with the single exception of Abu Dhabi, no market regulates a longevity clinic at all. It regulates the premises through a general facility license, the cell therapies through product or safety law, and the tests through device and laboratory law, and it does so through three different authorities that do not coordinate around the word longevity because the word has no legal meaning in their frameworks. The clinic is the place where three unrelated regimes happen to meet under one brand.

That reframes the only question worth asking. Not is this clinic regulated, because the answer is almost always yes and it almost never means what it sounds like. The question is which regime each specific service falls under, and in this market is that regime a real approval, a safety notification or a non-binding guideline. The same clinic can hold a spotless facility license, run its bloods in an accredited lab and still deliver a cell therapy that no product regulator has approved, and all three of those facts can be true at once because they answer to three different regulators. India is the sharpest illustration, where the National Guidelines for Stem Cell Research 2017 state that no stem cell therapy is an approved standard of care other than blood stem cell transplantation and that everything else is investigational, while the guidelines themselves carry no statutory penalty, so the binding hook is the separate New Drugs and Clinical Trials Rules 2019, which classify a stem-cell-derived product as a new drug requiring central approval.3839 Strict on paper, statutory only in part, and enforced by an agency the literature describes as under-resourced.40 India is mapped at India, the wider picture at Asia and Europe, and the United States at the United States.

A clinic can be perfectly licensed and still owe its most important claim to a regulator that has never heard of it.

Cite this article: Healthspan Economy, “Longevity Clinic Regulation, Market by Market (2026),” healthspaneconomy.com. Free to cite with attribution.

Footnotes

  1. Department of Health Abu Dhabi, “Healthy Longevity Medicine Clinic Standard,” Document Ref DOH/SD/HLMCS/HCF/V1/2024, publication October 2024, effective April 2025. The standard sets staffing, eligibility and evidence-tier ratings, including the diagnostic tier “not recommended outside of research protocol” and the cautionary intervention tiers cited. https://www.doh.gov.ae/-/media/DOH/StanddardOfLogeivity.ashx ↩ ↩2

  2. Department of Health Abu Dhabi, “Abu Dhabi sets standards for the world’s first Healthy Longevity Medicine Centres,” October 31, 2024. https://www.doh.gov.ae/en/news/abu-dhabi-sets-standards-for-the-world-first-healthy-longevity-medicine-centres ↩

  3. Department of Health Abu Dhabi, “Department of Health Abu Dhabi licenses Institute for Healthier Living Abu Dhabi as the world’s first specialised Healthy Longevity Medicine Centre,” November 19, 2024. https://www.doh.gov.ae/en/news/doh-licenses-institute-for-healthier-living-ad-longevity-medicine-centre ↩

  4. Government of Dubai Media Office, “Mohammed bin Rashid issues law establishing Dubai Longevity Authority,” June 10, 2026. Law No. 17 of 2026 establishes the Dubai Longevity Authority to license and supervise the value chain from research and clinical trials to patient clinics. https://mediaoffice.ae/en/news/2026/jun/10-06/mohammed-bin-rashid-issues-law-establishing-dubai-longevity-authority ↩

  5. Dubai Health Authority, “Standards for Stem Cells and Regenerative Medicine,” Version 1, Code DHA/HRS/HPSD/ST-68, effective April 20, 2025. Binds stem cell and regenerative services in DHA-licensed facilities. https://www.dha.gov.ae/uploads/022025/Standards%20for%20Stem%20Cells%20and%20Regenerative%20Medicine202522994.pdf ↩

  6. Ministry of Health Singapore, Healthcare Services Act, list of licensable healthcare services (16 services, none longevity-specific); HCSA replaced the Private Hospitals and Medical Clinics Act. https://www.hcsa.gov.sg/about-us/5-list-of-specified-services/ and https://www.moh.gov.sg/others/health-regulation/healthcare-services-regulation-and-licensing/ ↩

  7. Care Quality Commission and Health and Social Care Act 2008 (Regulated Activities) Regulations 2014, Schedule 1 (14 regulated activities, none longevity-specific). https://www.legislation.gov.uk/uksi/2014/2936/schedule/1/made and https://www.cqc.org.uk/guidance-regulation/providers/registration/scope-registration/regulated-activities ↩

  8. Medical Care Act (Act No. 205 of 1948), Japan, facility classification by capacity, clinic establishment by notification under Article 8. Japanese Law Translation. https://www.japaneselawtranslation.go.jp/en/laws/view/2199/en ↩

  9. Medical Service Act, Republic of Korea, Article 3 series classifying medical institutions into three groups, none longevity-specific. Korea Legislation Research Institute. https://elaw.klri.re.kr/eng_mobile/ganadaDetail.do?hseq=39874&type=abc&key=MEDICAL+SERVICE+ACT&param=M ↩

  10. Ministry of Health Saudi Arabia, “Healthcare Investor Licensing Guide,” enumerating licensable facility types (hospital, polyclinic, clinic, laboratory and others), none longevity-specific; governed by the Law of Private Health Institutions. https://www.moh.gov.sa/en/eServices/Licences/Documents/Healthcare-Investor-Licensing-Guide.pdf ↩

  11. US clinic and physician licensing is a state function with no federal clinic license; a targeted review of state stem-cell statutes (California, Texas, Florida) found disclosure and physician-conduct rules but no state defining a longevity-clinic category as of July 2026. See California SB 512 (2017), Texas HB 810 (2017), Florida SB 1768 (2025). https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201720180SB512 ; https://capitol.texas.gov/tlodocs/85R/billtext/html/HB00810F.htm ; https://www.flsenate.gov/Session/Bill/2025/1768/BillText/er/HTML ↩

  12. US Food and Drug Administration, 21 CFR 1271.10, four criteria for regulation solely as a human cell or tissue product; and the “Framework for the Regulation of Regenerative Medicine Products.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.10 and https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/framework-regulation-regenerative-medicine-products ↩

  13. US Food and Drug Administration, “Questions and Answers Regarding the End of the Compliance and Enforcement Policy,” enforcement discretion for certain HCT/Ps ended May 31, 2021. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/questions-and-answers-regarding-end-compliance-and-enforcement-policy-certain-human-cells-tissues-or ↩

  14. US Food and Drug Administration, “Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes,” dated July 22, 2020, updated April 9, 2024: no FDA-approved exosome products; the only approved stem cell products are cord-blood-derived and only for blood disorders. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes ↩ ↩2

  15. Regulation (EC) No 1394/2007 on advanced therapy medicinal products (adopted November 13, 2007), requiring central marketing authorization via the European Medicines Agency; Article 28 inserts the hospital exemption into Directive 2001/83/EC for products prepared on a non-routine basis for an individual patient. Facility licensing is a member-state competence under Article 168(7) TFEU. https://eur-lex.europa.eu/eli/reg/2007/1394/oj/eng and https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview ↩

  16. UK Medicines and Healthcare products Regulatory Agency, hospital-exemption guidance under the Human Medicines Regulations 2012 (conditions: non-routine basis, individual prescription, used in a hospital); Human Tissue Authority licensing of tissue and cell establishments under the Human Tissue (Quality and Safety for Human Application) Regulations 2007. https://assets.publishing.service.gov.uk/media/67c9ca8aae2aa47d2f5ae3e6/26_a_Guidance_on_the_UK_s_arrangements_under_the_hospital_exemption_scheme_clean__1_.pdf and https://www.hta.gov.uk/guidance-professionals/guidance-sector/human-application ↩

  17. Swissmedic, legal framework governing tissues and cells and advanced therapy medicinal products; substantially manipulated cells (including cell expansion) are transplant or medicinal products requiring Swissmedic authorization under the Therapeutic Products Act (SR 812.21); unauthorized cell products are permitted only in authorized trials or under the individual-import route. Facility licensing is cantonal. https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/besondere-arzneimittelgruppen—ham-/innovation/publikationen/legal-basis-governing-the-use-of-tissues-and-cells-of-human-orig.html ↩

  18. Therapeutic Goods Administration, “Autologous human cells and tissues products regulation,” reforms effective from July 2018 narrowing the autologous exclusion; biologicals and excluded autologous HCT products must not be advertised to consumers. https://www.tga.gov.au/sites/default/files/autologous-human-cells-and-tissues-products-regulation.pdf ↩

  19. Paul-Ehrlich-Institut, authorization of non-routinely manufactured advanced therapy medicinal products under Section 4b of the Arzneimittelgesetz (hospital exemption); private clinics licensed generally under Section 30 of the Gewerbeordnung. https://www.pei.de/EN/regulation/approvals/authorisation-atmp/authorisation-atmp-node.html ↩

  20. Läkemedelsverket (Swedish Medical Products Agency) authorizes hospital-exemption ATMP manufacture under national regulations (LVFS series); private healthcare providers register with the Health and Social Care Inspectorate (IVO) under the Patient Safety Act (2010:659). https://www.ivo.se/other-languages/report-activities/healthcare-provider-register/ ↩

  21. Lægemiddelstyrelsen (Danish Medicines Agency) administers the EU ATMP hospital exemption and requires a manufacturing authorization; treatment sites register with the Danish Patient Safety Authority (Styrelsen for Patientsikkerhed). https://laegemiddelstyrelsen.dk/en/special/regulation-of-innovative-medicinal-products-including-atmp/ and https://stps.dk/sundhedsfaglig/registrering/behandlingssted/hvilke-behandlingssteder-skal-registreres ↩

  22. Saudi Food and Drug Authority, “Guideline on Classification of Advanced Therapy Medicinal Products,” Version 1.0, issued November 6, 2023, capturing gene therapy, somatic cell therapy and tissue-engineered products (marketing authorization required); SFDA reported approving roughly ten gene and cell therapy trials since 2020. https://www.sfda.gov.sa/sites/default/files/2023-11/ClassificationAdvancedTherapyGV01.pdf and https://www.sfda.gov.sa/en/news/4050126 ↩

  23. US Food and Drug Administration, Warning Letter to Dynamic Stem Cell Therapy (Henderson, NV), February 11, 2026, for marketing umbilical-cord-derived cells and exosomes without a Biologics License Application. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dynamic-stem-cell-therapy-712579-02112026 ↩

  24. EuroStemCell, “Stem cell tourism: selling hope through unproven stem cell treatments, lessons from the X-Cell-Center.” The XCell-Center closed in 2011 after reported patient harm; this case predates and motivated Germany’s current Section 4b AMG regime. Authoritative secondary source (regulator contemporaneous statements not retrievable). https://www.eurostemcell.org/stem-cell-tourism-selling-hope-through-unproven-stem-cell-treatments-lessons-x-cell-center ↩

  25. Act on the Safety of Regenerative Medicine (Act No. 85 of 2013, in force November 25, 2014), Japan, with a three-class risk system and provision plans reviewed by certified committees for safety and provision standards rather than efficacy. Japanese Law Translation and Ministry of Health, Labour and Welfare overview. https://www.japaneselawtranslation.go.jp/en/laws/view/4980/en and https://www.mhlw.go.jp/content/10808000/000565836.pdf ↩ ↩2

  26. Pharmaceuticals and Medical Devices Agency, regenerative medical products and the conditional and time-limited approval pathway under the Pharmaceuticals and Medical Devices Act. https://www.pmda.go.jp/english/review-services/reviews/0003.html ↩

  27. Ministry of Health, Labour and Welfare, Act Amending Parts of the Regenerative Medicine Safety Act and the Clinical Research Act (Act No. 51 of 2024, promulgated June 14, 2024), extending the regime to in-vivo gene therapy and adding inspection and disqualification powers over certified committees; enforcement by Cabinet Order within one year of promulgation. https://www.mhlw.go.jp/content/001265334.pdf and https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000150542_00016.html ↩

  28. Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products (Act No. 16556 of 2019, in force August 28, 2020), Republic of Korea, with a three-tier risk classification and MFDS approval and product roles. Korea Legislation Research Institute and Ministry of Food and Drug Safety. https://elaw.klri.re.kr/eng_service/lawView.do?hseq=56486&lang=ENG and https://mfds.go.kr/eng/brd/m_61/view.do?seq=46 ↩

  29. 2024 amendment to Korea’s Advanced Regenerative Bio Act, reported effective February 21, 2025, creating a new category of “advanced regenerative medicine treatment” that permits designated institutions to provide the therapy as billable care to patients with serious, rare or incurable conditions. The official English statutory text was not yet published at the time of writing; article numbers, the approval term and the effective date rest on a peer-reviewed comparative analysis and reputable reporting and should be confirmed against the Korean original. https://pmc.ncbi.nlm.nih.gov/articles/PMC13083794/ and https://parentsguidecordblood.org/en/news/south-korea-expands-access-regenerative-medicine-serious-illnesses ↩ ↩2

  30. Regulation (EU) 2017/746 on in vitro diagnostic medical devices (date of application May 26, 2022), with notified-body assessment for higher-risk classes and transitional timelines extended by Regulation (EU) 2024/1860 running to 2027 and beyond. https://eur-lex.europa.eu/eli/reg/2017/746/oj ↩

  31. Clinical Laboratory Improvement Amendments, administered by the Centers for Medicare and Medicaid Services, 42 CFR Part 493, regulating clinical laboratory testing on humans. https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments and https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493 ↩

  32. US Food and Drug Administration, laboratory-developed tests. The May 2024 final rule bringing LDTs under device regulation was vacated by the US District Court for the Eastern District of Texas on March 31, 2025, and the FDA reverted the regulation on September 19, 2025, leaving LDTs overseen chiefly under CLIA. https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests ↩

  33. Health Sciences Authority Singapore, “Regulatory Guidelines for Laboratory Developed Tests (LDTs),” guideline GL-08, under the Health Products Act; clinical laboratories are licensed by the Ministry of Health under the Healthcare Services Act. https://www.hsa.gov.sg/docs/default-source/hprg-mdb/guidance-documents-for-medical-devices/gl-08-r1-regulatory-guidelines-for-laboratory-developed-tests-(ldts)-(2023-mar)-pub.pdf ↩

  34. Therapeutic Goods Administration, “Regulatory requirements for in-house IVDs,” Version 3.0, May 2024: Class 1 to 3 in-house IVDs require NATA accreditation to ISO 15189 and are exempt from the register; Class 4 must be included in the Australian Register of Therapeutic Goods. https://www.tga.gov.au/sites/default/files/regulatory-requirements-in-house-ivds.pdf ↩

  35. Switzerland, revised Federal Act on Human Genetic Testing (GUMG), reported to extend regulation to genetic tests outside the medical context, including lifestyle and nutrition tests, and to restrict direct-to-consumer testing. The entry-into-force date and exact scope rest on secondary analyses locating the federal text and should be confirmed against Fedlex (SR 810.12) and the Federal Office of Public Health. https://www.fedlex.admin.ch/eli/cc/2022/537/en ↩

  36. Republic of Korea, Bioethics and Safety Act, direct-to-consumer genetic testing permitted only within a certified list of items administered by the Ministry of Health and Welfare. https://elaw.klri.re.kr/eng_service/lawTwoView.do?hseq=15979 ↩

  37. Japan, Medical Care Act quality-assurance standards for clinical laboratory testing (amended 2017, enforced from December 2018) apply to tests ordered as medical practice; direct-to-consumer genetic testing sold outside a physician relationship appears to fall largely outside these controls, and no dedicated binding instrument regulating it was found in the primary sources checked as of July 2026. https://www.mhlw.go.jp/file/05-Shingikai-10801000-Iseikyoku-Soumuka/0000192662.pdf ↩

  38. National Guidelines for Stem Cell Research 2017, Indian Council of Medical Research and Department of Biotechnology: no approved indications for stem cell therapy other than hematopoietic stem cell transplantation, all other use investigational. Guidelines, not a statute, with no standalone criminal penalty. https://dbtindia.gov.in/regulations-guidelines/guidelines/national-guidelines-stem-cell-research-%E2%80%93-2017 ↩

  39. New Drugs and Clinical Trials Rules 2019, India (G.S.R. 227(E), March 19, 2019), classifying a stem-cell-derived product as a new drug requiring central approval through the Central Drugs Standard Control Organisation. https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/New-Drugs/ ↩

  40. Peer-reviewed analysis characterizing the gap between India’s 2017 stem-cell guidelines and clinical practice as regulatory arbitrage, noting that guideline breaches carry no legal sanction and that enforcement capacity is limited. Journal of Law and the Biosciences, 2025. Used to characterize the enforcement gap, not as a primary regulatory instrument. https://academic.oup.com/jlb/article/12/2/lsaf027/8329365 ↩